详情页 - 聚合机构库演示平台

资源类型：

文章类型：

作者：

Gui, Lin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] * ; Cheng, Ying[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wang, Huaqing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Cao, Junning[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li, Zhenling[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhang, Lei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Gao, Yuhuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li, Yufu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xu, Weijie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Li, Xiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Ke, Xiaoyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Jing, Hongmei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zhang, Qingyuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Xi, Yaming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Liu, Tingbo[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Wang, Zhen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Gao, Yajie[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Pan, Qin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Zou, Liqun[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ; Shi, Yuankai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18] ;

单位： [1]Chinese Acad Med Sci Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [2]Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China [3]Nankai Univ, Affiliated Hosp, Tianjin Peoples Hosp, Tianjin, Peoples R China [4]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [5]China Japan Friendship Hosp, Beijing, Peoples R China [6]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [7]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [8]Henan Canc Hosp, Zhengzhou, Peoples R China [9]Jilin Canc Hosp, Changchun, Peoples R China [10]Tianjin Peoples Hosp, Tianjin, Peoples R China [11]Peking Univ Third Hosp, Beijing, Peoples R China [12]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [13]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China [14]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China [15]Linyi Canc Hosp, Linyi, Peoples R China [16]Dalian Med Univ, Affilicated Hosp 1, Dalian, Peoples R China [17]Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Peoples R China [18]Sichuan Univ, West China Hosp, Chengdu, Peoples R China

出处：

DOI：

ISSN：

基金：

语种：

WOS：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2020]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者单位： [1]Chinese Acad Med Sci Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp, Beijing, Peoples R China [2]Jilin Canc Hosp, Dept Med Oncol, Changchun, Peoples R China [3]Nankai Univ, Affiliated Hosp, Tianjin Peoples Hosp, Tianjin, Peoples R China [4]Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China [5]China Japan Friendship Hosp, Beijing, Peoples R China [6]Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China [7]Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China [8]Henan Canc Hosp, Zhengzhou, Peoples R China [9]Jilin Canc Hosp, Changchun, Peoples R China [10]Tianjin Peoples Hosp, Tianjin, Peoples R China [11]Peking Univ Third Hosp, Beijing, Peoples R China [12]Harbin Med Univ, Canc Hosp, Harbin, Peoples R China [13]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China [14]Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China [15]Linyi Canc Hosp, Linyi, Peoples R China [16]Dalian Med Univ, Affilicated Hosp 1, Dalian, Peoples R China [17]Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou, Peoples R China [18]Sichuan Univ, West China Hosp, Chengdu, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Interim results of a phase II multicenter study with the oral histone deacetylase inhibitor abexinostat in patients with relapsed/refractory follicular lymphoma

文献详情